platoseedplatoseed
Enabling Tissue Targeting of Therapies
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Eugit Therapeutics focuses on enabling tissue targeting of therapies. The company emphasizes tissue-targeting approaches and lists a leadership team with expertise in computational genomics, immunology, and genomics-derived fields, supported by a scientific advisor with Harvard affiliations.
The text indicates a focus on tissue targeting therapies, but provides no concrete description of product features, mechanisms, delivery modalities, or platform components beyond the overarching aim of tissue targeting. Concrete product details such as how targeting is achieved, delivery methods, or stages of development are not specified in the provided material.
Who it’s for: biotech/pharmaceutical researchers and developers seeking tissue-targeted therapeutic approaches, potentially including groups involved in genomics, immunology, and translational medicine.
funded company; notable academic affiliations and advisors
Nizar is the co-founder and CEO at EUGIT, which he started with George Church in 2022. He is an expert in cancer research, genomics and bioinformatics and has published over 25 articles in peer-reviewed journals such as Nature and has obtained nationally competitive grants. Prior to EUGIT, he was a scientist at 23andMe and a tenure track lecturer at the University of Edinburgh, UK. Nizar grew up in Toronto and obtained his PhD in Biophysics from Stanford.
Engineered gamma delta T-cells for off-the-shelf treatment of cancers
EUGIT Therapeutics develops off-the-shelf engineered gamma delta T cells to treat breast, ovarian, and prostate cancers, aiming to provide ready-to-infuse immune cell therapy. The company’s approach uses donor-derived gamma delta T cells gene-engineered to fight cancer, targeting cancers where existing immunotherapies have limited success.
From the original launch (Jul 2022) — may be outdated.
Formerly “EUGIT Tx” · why startups rename →
AI platform accelerating therapies for rare & inflammatory diseases.
Potent, durable, and redosable non-viral genetic medicines
